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Summary
The three known inhibitors of axonal regeneration
present in myelin—MAG, Nogo, and OMgp—all in-
teract with the same receptor complex to effect inhibi-
tion via protein kinase C (PKC)-dependent activation
of the small GTPase Rho. The transducing compo-
nent of this receptor complex is the p75 neurotrophin
receptor. Here we show that MAG binding to cerebel-
lar neurons induces - and then -secretase proteo-
lytic cleavage of p75, in a protein kinase C-dependent
manner, and that this cleavage is necessary for both
activation of Rho and inhibition of neurite outgrowth.
Introduction
The p75 neurotrophin receptor, which interacts with all
four known neurotrophins, initiates a plethora of signal-
ing cascades (Gentry et al., 2004; Hempstead, 2002).
Recently, p75 has also been shown to be the transduc-
ing component within the receptor complex for the
three known myelin inhibitors of axonal regeneration:
myelin-associated glycoprotein (MAG), a 66 amino acid
sequence of Nogo-A (Nogo-66), and oligodendrocyte-
myelin glycoprotein (OMgp) (Wang et al., 2002a; Wong
et al., 2002). These inhibitors all bind directly to the
Nogo receptor (NgR), so named for its initial identifica-
tion as a binding partner for Nogo-66 (Domeniconi et
al., 2002; Fournier et al., 2001; Liu et al., 2002; Wang et
al., 2002b). After binding ligand, NgR interacts with p75
in a manner that most likely also involves LINGO-1, a
third component of the receptor complex (Mi et al.,
2004). Downstream from their receptor binding, these
myelin inhibitors bring about inhibition of axonal growth
through the activation of the small GTPase Rho (Leh-
mann et al., 1999) in a protein kinase C (PKC)-depen-*Correspondence: filbin@genectr.hunter.cuny.edu
3 Present address: Molecular Neurobiology Program, Skirball Insti-
tute for Biomolecular Medicine, Departments of Cell Biology and
Physiology and Medicine, New York University School of Medicine,
540 First Avenue, New York, New York 10016.dent manner (Sivasankaran et al., 2004). While our un-
derstanding of the signaling initiated by myelin inhibitors
has grown considerably in recent years, the precise be-
havior of the molecular players in inhibiting axonal
growth is still far from clear.
A number of years ago, “shedding” of a 50 kDa frag-
ment of the extracellular domain (ECD) of p75 was re-
ported to occur in culture, largely from Schwann cells,
but also from some neurons (DiStefano and Johnson,
1988). This line of inquiry led more recently to the dem-
onstration that ectodomain shedding of p75 is pro-
moted by treatment with phorbol esters such as 12-
myristate 13-acetate (PMA) (Jung et al., 2003; Kanning
et al., 2003). PMA treatment results in the formation of
an intermediate 30 kDa C-terminal fragment (CTF) that
is further cleaved to yield a 25 kDa intracellular domain
(ICD) (Figure 1A). Moreover, neurotrophin treatment
does not induce cleavage of p75 (Jung et al., 2003;
Kanning et al., 2003). Although the functional relevance
of these cleavage events is unknown, sequential cleav-
age of p75 is reminiscent of regulated intramembrane
proteolysis (RIP), a novel mechanism in receptor signal-
ing typified by processing such different proteins as
Notch and amyloid precursor protein (APP) (Brown et
al., 2000; Ebinu and Yankner, 2002; Urban and Freeman,
2002). The initial cleavage of the ECD occurs through
the action of a membrane bound metalloprotease sim-
ilar to those of the ADAMS family of proteases and
generally termed an α-secretase (Hooper et al., 1997).
Initial cleavage by α-secretase is obligatory for the sec-
ond cleavage to occur within the transmembrane do-
main by a γ-secretase complex such as presenilin (Ko-
pan and Ilagan, 2004). In the case of Notch, the ICD is
released after the second cleavage into the cytoplasm,
where it quickly moves to the nucleus, signals differen-
tiation events, and is then rapidly degraded (Mumm
and Kopan, 2000). For the majority of receptors that
undergo RIP, however, the ICD does not move to the
nucleus. Instead, the ICD is typically degraded rapidly
in the cytoplasm (Ebinu and Yankner, 2002).
Here we report that the p75 receptor is cleaved se-
quentially by α- and γ-secretase activity, respectively,
in a PKC-dependent manner in order for MAG to inhibit
neurite outgrowth from cerebellar neurons. Further-
more, since MAG activation of Rho is blocked if secre-
tase activity is inhibited, it is likely that a proteolytic
fragment of p75 can mediate Rho activation.
Results
MAG and PKC-Dependent Proteolytic
Cleavage of p75
In cell lines transfected to express p75 in abundance
as well as in immortalized neuronal cell lines, cleavage
of p75 occurs following treatment with the PKC activa-
tor PMA (Jung et al., 2003; Kanning et al., 2003). The
resulting fragments are the ECD and a 30 kDa CTF that
is subsequently cleaved to a 25 kDa ICD fragment (Fig-
ure 1A). To assess if endogenous neuronal p75 is
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850Figure 1. MAG Induces PKC-Dependent Pro-
teolytic Cleavage of p75NTR
(A) The p75NTR ectodomain is initially shed
by metalloprotease-mediated cleavage. The
resulting p75NTR carboxy-terminal fragment
(CTF) is subsequently cleaved by γ-secre-
tase to release the p75NTR intracellular do-
main (ICD).
(B) Rat cerebellar neurons were treated with
inhibitors of different proteolytic enzymes,
epoxomicin (Epo, 1 M), TAPI-1 (1 M), in-
hibitor X (1 M), and of PKC, Gö6976 (100
nM), for 60 min before addition of MAG-Fc
or MAG(1-3)-Fc (both 20 g/ml, 30 min).
Western blots probed with an antibody spe-
cific to the cytoplasmic domain of p75NTR
revealed a MAG-stimulated proteolytic fragment (<, ICD) produced by an inhibitor X and Gö6976-sensitive, γ-secretase-mediated cleavage.
The ICD peptide is derived from a transitional product (*, CTF) that visibly accumulates in the presence of a γ-secretase or PKC inhibitor and
that is lost in the presence of the metalloproteinase inhibitor TAPI-1.cleaved in a similar manner in response to myelin- p
dbased inhibitors, we treated primary cerebellar neurons
from postnatal day 5–8 rats with soluble MAG chimeras
and analyzed the lysates by Western blotting with anti- I
bbody to the cytoplasmic domain of p75. It has been
reported before that p75 appears as a prominent 80 T
rkDa band along with other smaller bands that represent
heterogeneously glycosylated forms of the protein γ
p(Grob et al., 1985). To clarify the relationship between
proteolytic processing of p75 and MAG-induced signal- r
eing, we first added inhibitors of different proteolytic en-
zymes or a PKC inhibitor, followed by either of two e
achimeric forms of MAG. MAG-Fc comprises the entire
five Ig-like extracellular domains fused to the Fc portion c
cof human IgG and has been shown to inhibit axonal
growth (Tang et al., 1997). MAG (1-3)-Fc, which lacks c
othe fourth and fifth Ig-like domains, binds to neurons in
a specific, sialic acid-dependent manner, but it is not e
finhibitory (Tang et al., 1997). For p75 and other proteins
that undergo RIP processing, it has been reported that c
athe second cleavage leaves a cytoplasmic fragment
that is degraded too rapidly for detection unless a pro- b
teasome inhibitor is included (Kanning et al., 2003;
Oberg et al., 2001). Accordingly, the proteasome inhibi- n
ttor epoxomicin was first added to all cells. MAG-Fc
alone results in the appearance of a 25 kDa proteolytic s
dfragment (Figure 1B, lane 6) as well as a faint band at
w30 kDa. In the absence of epoxomicin, no cleavage t
fbands are visible (data not shown). The 30 kDa frag-
ment corresponds to the size of the transmembrane s
rand cytoplasmic domains after extracellular cleavage
with α-secretase (Figure 1A). In the presence of com- f
γpound X, a specific inhibitor of γ-secretase, the 30 kDa
fragment accumulates without subsequent cleavage to o
25 kDa, demonstrating the role of γ-secretase in this
second cleavage reaction (Figure 1B, lane 8). Identical I
aresults are seen in the presence of Gö6976, an inhibitor
of PKC (lane 9), suggesting that γ-secretase is PKC de- T
apendent. The general inhibitor of the ADAM metallopro-
tease family, TAPI-1, abolishes extracellular cleavage e
iand subsequent γ-secretase cleavage (lane 7). Finally,
in the presence of a control chimera, MAG(1-3)-Fc s
F(lanes 2–5), or without addition of any ligand (data not
shown), there is no cleavage of p75. These results sug- t
agest that MAG binding to primary neurons induces RIProcessing of p75, in a PKC-dependent manner, to pro-
uce a final ICD p75 fragment of about 25 kDa.
nhibition of Neurite Outgrowth by MAG Is Blocked
y Secretase Inhibition
o determine if MAG-induced RIP processing of p75 is
equired for the inhibitory effects of MAG, we blocked
-secretase activity by adding a specific inhibitor, com-
ound X, to the neurite outgrowth assay. As we have
eported before (Mukhopadhyay et al., 1994), when cer-
bellar neurons are cultured on a monolayer of MAG-
xpressing CHO cells, they extend processes that are
bout 70% shorter than when grown on control CHO
ells not expressing MAG (Figures 2A and 2B). In sharp
ontrast, however, when the γ-secretase inhibitor is in-
luded in the cocultures, MAG has no effect on neurite
utgrowth; processes are the same length on MAG-
xpressing cells as on control cells. Similar results were
ound when an α-secretase inhibitor, TAPI-1, was in-
luded in the cocultures. The PKC inhibitor Go6976
lso completely blocked inhibition of neurite outgrowth
y MAG (Sivasankaran et al., 2004).
As well as using MAG expressed by live cells in the
eurite outgrowth assay, we also assessed if the inhibi-
ory effects of soluble MAG-Fc could be blocked by
ecretase inhibitors. Figures 2C and 2D show that in-
eed a γ-secretase inhibitor completely blocks inhibi-
ion by MAG-Fc. These results, together with those
rom neurons growing on MAG-expressing CHO cells,
trongly suggest that MAG binding to cerebellar neu-
ons leads to an obligatory two-stage cleavage of p75,
irst by an α-secretase and then via a PKC-dependent
-secretase, to generate MAG’s inhibitory effects on ax-
nal growth.
nhibition by MAG Is Blocked in Neurons Expressing
n Uncleavable Form of p75
o complement the pharmacological results described
bove, uncleavable forms of p75 were used (Zampieri
t al., 2005). Chimeric proteins were created by replac-
ng either the transmembrane (TM) or the extracellular
talk domain of p75 with equivalent domains from the
as receptor. Both p75 and Fas are members of the
umor necrosis factor (TNF) receptor superfamily, and
lthough they each contain similar domains, unlike p75,
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851Figure 2. Inhibition of Neurite Outgrowth by MAG Is Blocked by Secretase Inhibition
(A) Neurite outgrowth of rat cerebellar neurons cultured onto confluent monolayers of control or MAG-expressing CHO cells in the presence
of epoxomicin (Epo, 1 M), TAPI-1 (1 M), inhibitor X (1 M), or Gö6976 (100 nM).
(B) Average neurite lengths on MAG-expressing cells were significantly longer in the presence of enzyme inhibitors (**p < 0.001).
(C) Neurite outgrowth of rat cerebellar neurons cultured onto an L1-Fc substrate in the presence of MAG-Fc (20 g/ml) and inhibitor X (1 M).
(D) Average neurite lengths from neurons cultured in the presence of inhibitor X and MAG-FC were significantly longer than those cultured
with MAG-Fc alone (**p < 0.001).Fas does not undergo RIP. Figure 3A is a diagram repre-
senting the chimeric proteins. The protein in which the
TM domain is replaced is termed p75-FasTM, and the
protein where the stalk domain is replaced is termed
p75-FasS. Following transfection into NG108, both of
these chimeric proteins are expressed at significantly
higher levels (5- to 6-fold) than endogenous p75 (see
Figure S1A in the Supplemental Data online). In addi-
tion, from surface biotinylation and precipitation studies
we show that each reaches the cell surface and is able
to interact with the NgR receptor (Figures S1B and
S1D). When the wild-type p75 is expressed in 293 cells,
both thew30 kDa CTF and thew25 kDa ICD are clearly
visible after PMA treatment (Figure 3B). For the p75-
FasTM chimera, only the w30 kDa fragment appeared
after PMA treatment, while the p75-FasS chimera, un-
der similar conditions, did not display any cleaved
products. This lack of cleavage of the p75-FasTM chi-
mera is consistent with the localization of the γ-secre-
tase site in the transmembrane domain (Zampieri et al.,
2005). In contrast, for the p75-FasS chimera, only the
α-secretase site is lost from p75, and although the p75
γ-secretase site is present in the chimera, cleavage at
the γ site must be preceded by cleavage at the α-secre-
tase site. Hence, no γ cleavage occurred in the p75
FasS chimera.
To assess the role of p75 cleavage directly on inhibi-
tion of neurite outgrowth by MAG, these chimeric re-
ceptors were, first, each expressed in the neuronal cell
line NG108, which had previously been shown to ex-
press wild-type p75 and to be inhibited by MAG and
myelin (Domeniconi et al., 2002). When these NG108
cells expressing either of the chimeric forms of p75
were grown on MAG-expressing CHO cells, they werenot inhibited from extending processes; growth was the
same as on the control cells not expressing MAG. As a
control, overexpression of wild-type p75 had no effect
on inhibition by MAG (Figures 3C and 3D). Furthermore,
when a cDNA coding for only the ICD of p75 is trans-
fected into NG108 cells, neurite outgrowth on the con-
trol cells, not expressing MAG, is inhibited to the same
extent as on MAG-expressing cells. This indicates that
the ICD of p75 is, alone, sufficient to inhibit neurite out-
growth in the absence of MAG. Next, the chimeric re-
ceptors were each expressed in primary, dorsal root gan-
glion (DRG) neurons. As with the NG108 cells, the DRG
neurons expressing either of the chimeric receptors are
not inhibited by MAG; growth on MAG-expressing cells is
the same as on the control cells not expressing MAG (Fig-
ure 3E). Also like the NG108 cells, overexpression of wild-
type p75 has no effect on inhibition by MAG (Figure 3E).
Therefore, expression of the cleavage-resistant p75
constructs in neurons blocked inhibition by MAG, con-
firming the results obtained by pharmacological inhibi-
tors, namely that MAG-induced cleavage of p75 is cru-
cial to effect inhibition.
Activation of Rho by MAG Is Blocked
by Secretase Inhibition
Numerous reports have described the p75-mediated
activation of Rho in response to each of the known my-
elin inhibitors (Mi et al., 2004; Wang et al., 2002a; Ya-
mashita et al., 2002). To determine if cleavage of p75 is
required for activation of Rho by MAG, we precipitated
activated Rho with the GST-Rho binding domain (RBD)
of rhotekin, a protein that binds only to GTP-Rho. Fig-
ure 4 shows a Western blot of the precipitates, immu-
nostained for Rho. As has been reported before (Ya-
Neuron
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(A) Schematic diagram of the p75 chimeric constructs.
(B) HEK293 cells were transfected with a chimeric construct where the transmembrane domain (p75-FasTM) or the stalk domain (p75-FasS)
of p75 was replaced with the equivalent domains from FasR. Wild-type p75 was included as a control. After transfection, the cells were
incubated 45 min with PMA (100 ng/ml). Lysates were analyzed by Western blot using 9992 antisera against the intracellular domain of p75.
(C) NG108 cells expressing the p75 chimeric receptors were cultured on confluent monolayers of control or MAG-expressing cells. Average
neurite lengths from transfected cells were significantly longer as compared to untransfected cells (*p < 0.05). Expression of p75-ICD inhibited
neurite outgrowth from NG108-15 cells cultured on control cells monolayers (*p < 0.05).
(D) Neurite outgrowth from NG108 cells cultured on confluent monolayers of control or MAG-expressing CHO cells after transfection with
wild-type p75, chimeric p75 receptors, or p75-ICD.
(E) P5 DRG neurons transfected with either wild-type p75, the p75 chimeric receptors, or GFP alone grown on confluent monolayers of control
or MAG-expressing CHO cells. The mean neurite lengths from neurons transfected with the chimeric receptors were significantly longer as
compared to neurons transfected with wild-type p75 or GFP alone (*p < 0.05).mashita and Tohyama, 2003), binding of MAG-Fc to s
ccerebellar neurons induces the activation of Rho (Fig-
ure 4, lane 5). As expected, Rho activity in response to t
aMAG(1-3)-Fc is comparable to that seen in the unstimu-
lated control (Figure 4, lanes 1 and 2). The MAG-Fc- a
induced activation of Rho is returned to baseline levels
in the presence of a γ-secretase inhibitor, an α-secre-
tase inhibitor, or either of two inhibitors of PKC (Figure
4, lanes 6–9). The results indicate that MAG activation
of Rho requires RIP processing of the p75 neurotro-
phin receptor.
Discussion
Based on the results reported here, we propose a
mechanism of how myelin inhibitors act: MAG induces
cleavage of p75, a component of the NgR complex, by F
bactivating a membrane-associated α-secretase com-
plex. Cleavage by α-secretase results in shedding of R
cthe extracellular domain of p75 and is obligatory for a
osecond proteolytic cleavage by a γ-secretase complex,
(characteristic of RIP and requiring activation of PKC.
l
Cleavage by γ-secretase releases the ICD of p75, which n
is necessary for Rho activation and, in turn, initiates the w
adownstream steps that inhibit axonal growth. Strongupport for this model derives from both pharmacologi-
al and genetic data presented; inhibitors of α-secre-
ase, γ-secretase, or PKC each block activation of Rho
nd inhibition by MAG. Likewise, expression of cleav-
ge-resistant forms of p75 also block inhibition byigure 4. Activation of Rho by MAG Is Blocked by Secretase Inhi-
ition
ho activation detected by Rothekin-RBD pull-down assays in rat
erebellar neurons treated with MAG-Fc (20 g/ml) in the presence
f inhibitors of proteolytic enzymes, TAPI-1 (1 M), inhibitor X
1 M), and of PKC, Gö6976 (100 nM), calphostin C (100 nM). Base-
ine activation was determined in untreated or MAG(1-3)-Fc-treated
eurons. Positive and negative controls were obtained by loading
ith GTP or GDP, respectively. Blots were probed with an antibody
gainst Rho (-A, -B, -C).
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853MAG, while expression of the p75 ICD alone is suffi-
cient to effect inhibition in the absence of MAG. Fur-
thermore, since MAG, Nogo-66, and OMgp all serve as
ligands for the same receptor complex (Domeniconi et
al., 2002; Fournier et al., 2001; Liu et al., 2002; Wang et
al., 2002b) and all activate Rho (Lehmann et al., 1999;
Wang et al., 2002b; Yamashita et al., 2002), we also pro-
pose that this mechanism of action is very likely to be
the same for all three inhibitors.
These results are important for at least two reasons.
First, the identification of secretase activity in the sig-
naling by myelin inhibitors points to an attractive target
for therapeutic intervention in the treatment of CNS in-
jury. Blocking secretase activity has the potential to halt
the inhibition of axonal regeneration launched by the
binding of myelin-derived ligands to the p75 receptor
complex. Second, our results provide a physiological
basis for cleavage of p75 by α- and γ-secretases.
Myelin inhibitors are well known to activate Rho via
p75 to bring about inhibition of axonal growth (Derg-
ham et al., 2002; Lehmann et al., 1999; Yamashita et al.,
1999). In unraveling the transducing steps involving
p75, it has been suggested that in the absence of li-
gand, p75 exists in a complex with Rho and Rho-GDI,
the Rho GDP dissociation inhibitor that stabilizes the
inactive Rho state (Yamashita and Tohyama, 2003). In
that model, ligand binding to p75 is proposed to dis-
place Rho-GDI and thereby permit Rho activation, in
spite of the fact that MAG or Nogo binding appears to
strengthen the stability of the p75:Rho:Rho-GDI com-
plex. The implication is that Rho would remain inactive
after ligand binding. However, it was also reported in
the same study that a peptide fragment from the cyto-
plasmic domain of p75 was, on its own, capable of di-
minishing the inhibitory activity of Rho-GDI to permit
Rho activation to its GTP bound state (Yamashita and
Tohyama, 2003). The results we report here clarify the
apparent discrepancy reported in this previous study.
We suggest that the immediate effect of ligand binding
is to stabilize the ligand:p75:Rho:Rho-GDI complex,
maintaining Rho in an inactive state. Upon cleavage,
however, the ICD fragment of p75 displaces Rho-GDI
from Rho, and activation is induced. Thus, the previous
observation that a soluble fragment of p75, in the ab-
sence of ligand, can both reduce the activity of Rho-
GDI and activate Rho and the results presented here
showing a similar p75 ICD fragment can inhibit neurite
outgrowth are consistent with our new model.
The p75 receptor is a member of the tumor necrosis
factor receptor (TNF-R) family of molecules. Recently,
another member of this family of molecules, TROY (also
known as TAJ), was shown to be capable of substitut-
ing for p75 to effect inhibition (Park et al., 2005; Shao
et al., 2005). TROY interacts with NgR and LINGO-1:
expression of TROY, NgR, and LINGO-1 in COS cells
results in activation of Rho in response to myelin-asso-
ciated inhibitors, and blocking TROY blocks inhibition.
However, although neurons from TROY−/− mice extend
longer processes on low concentrations of myelin in-
hibitors, at higher concentrations they are inhibited
(Shao et al., 2005). This suggests that other molecules
such as p75 are present to bring about inhibition. The
identification of TROY as a functional homolog for p75
explains the apparent paradox that neurons that do notexpress p75 are still inhibited by myelin. We now know
these neurons express TROY (Park et al., 2005; Shao et
al., 2005). Because we show that inhibition of neurite
outgrowth by MAG of cerebellar neurons, which ex-
press both p75 and TROY, requires secretase activity,
this suggests that TROY is also likely to undergo RIP.
This remains to be determined.
The number of cell surface proteins reported to un-
dergo RIP continues to grow (Brown et al., 2000; Urban
and Freeman, 2002). For the majority of these recep-
tors, the released ICD is immediately degraded in the
cytoplasm without any associated signaling. For a few
other receptors, such as Notch, the ICD contains a
transcriptional activator motif, and it translocates to the
nucleus to activate transcription of target genes (Fryer
et al., 2002; Mumm and Kopan, 2000; Nam et al., 2003).
Nuclear localization of the Notch ICD is transient, and
the time from release to degradation is rapid. Indeed,
as we report here for the cleaved p75 ICD, the Notch
ICD can be detected only after proteasome inhibition
(Oberg et al., 2001). We do not know if the p75 ICD
translocates after Rho activation to the nucleus to ef-
fect further signaling. The rapid rate of p75 ICD degra-
dation does not implicate the ICD fragment in any
specific metabolic fate.
In addition to its function in signaling inhibition by
key myelin ligands, p75 associates with at least 15 dif-
ferent effectors and has been shown to be involved in
both neurotrophic survival pathways and apoptotic
pathways (Gentry et al., 2004; Hempstead, 2002). It also
interacts with the other family of neurotrophin recep-
tors, the Trks. Interaction between receptors increases
the affinity of neurotrophin binding to result in an en-
hanced survival signal (Casaccia-Bonnefil et al., 1999;
Chao and Hempstead, 1995). The final cleavage prod-
uct of p75, the ICD, has been shown to be unable to
interact with Trks, leading to the suggestion that a dis-
ruption in the Trk:p75 association diminishes the sur-
vival pathway (Jung et al., 2003). Furthermore, others
have shown that apoptosis increases in transgenic
mice that express a cytoplasmic domain of p75 (Maj-
dan et al., 1997). It is not clear that this fragment is
identical to the p75 fragment released by γ-secretase
activity; nor is it clear that the two fragments behave
identically. It is important to note, however, that we did
not observe any increase in neuronal death in response
to MAG or myelin, nor when we expressed the p75 ICD
in NG108 cells (data not shown). What we have been
able to show is that neurotrophins can overcome inhibi-
tion by MAG and myelin in general, but only if the neu-
ron is exposed to the neurotrophin prior to being ex-
posed to inhibitor (Cai et al., 1999). When neurons are
exposed to inhibitor and neurotrophins at the same
time, the neurotrophins have no effect. One possible
explanation for this observation is that the inhibitory
ligand disrupts the Trk:p75 association and thereby di-
minishes the signal required to overcome inhibition.
In summary, our current results add another layer of
regulation to the mechanism of how myelin inhibitors
activate Rho via the p75 receptor to cause inhibition of
axonal growth. We can now add RIP processing, with
the proteolytic release of the ICD of p75 by γ-secretase
Neuron
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Experimental Procedures
p75 Cleavage Assay S
P6–P8 rat cerebellar neurons were cultured overnight in SATO me-
dium. Cells were pretreated for 60 min with epoxomicin (1 M),
T
w
TAPI-1 (1 M), inhibitor X (1 M), Gö6976 (100 nM), calphostin (100
nM), or DMSO vehicle control and subsequently stimulated for 30 A
min with MAG-Fc (20 g/ml), MAG(1-3)-Fc (20 g/ml), or vehicle
control. Cells were then washed one time with cold PBS on ice,
W
lysed in RIPA buffer and protease inhibitors, and centrifuged 5 min
T
at 14,000 × g; supernatants were quantified by BCA assay (Pierce)
r
for use in SDS-PAGE.
i
N
Rho Assay f
P6–P8 rat cerebellar neurons were cultured overnight in SATO me- p
dium. Cells were stimulated 30 min with individual inhibitors or ap-
propriate controls in the presence or absence of TAPI-1 (1 M),
Rinhibitor X (1 M), Gö6976 (100 nM), and calphostin (100 nM). GTP-
RRho was precipitated by using beads with GST-Rho binding do-
Amain (RBD) of rhotekin following the manufacturer’s instructions
P(Upstate Biotechnology).
R
Western Blotting
Cell lysate was separated by SDS-PAGE using 12% Precision gels B
(Pierce). For detection, proteins were transferred electrophoreti- l
cally to nitrocellulose membrane. Membranes were then blocked in f
5% nonfat dry milk in PBS. Incubation in a 1:2000 dilution of 9992
Cantiserum specific for the intracellular domain p75 or 1:1000 of
Panti-Rho antibody (Santa Cruz) in blocking buffer was performed
eovernight at 4°C. Membranes were washed three times in PBS with
N0.05% Tween-20. Secondary goat anti-rabbit HRP-conjugated anti-
Cbody (Sigma) was diluted 1:10,000 in blocking buffer and incubated
iwith the membranes for 1 hr at room temperature. Membranes
were then washed as before and developed using ECL (Amer- C
sham Biosciences). t
D
aNeurite Outgrowth Assay
mNeurite outgrowth assays were performed as described previously
(Mukhopadhyay et al., 1994). Briefly, dissociated P5–P8 rat cerebel- D
lar neurons or NG108 cells were plated at a density of 3 × 104 cells/ t
ml onto confluent monolayers of control and MAG-expressing CHO A
cells. After 16–18 hr of incubation in the presence or absence of D
TAPI-1 (1 M), inhibitor X (1 M), or Gö6976 (100 nM), cultures were N
fixed for 30 min with 4% paraformaldehyde, permeabilized with ice- M
cold methanol, and immunostained with an antibody against a neu- t
ron-specific β-tubulin (Tuj-1, Covance). Neurite lengths were mea-
Esured from at least 150 neurons per condition, from duplicate wells
tand from three independent experiments, and were quantified as
Fdescribed previously (Mukhopadhyay et al., 1994).
t
tTransfection and Differentiation of NG-108 Cells
Fand Transfection of Primary Neurons
(The construction of the p75-Fas chimeric receptors and the p75-
tICD receptor was described previously. The constructs were trans-
1fected into NG108 cells using lipofetamine (Life Technologies).
Upon transfection, NG108 cells were differentiated with dibutyryl- G
cAMP (1 mM) for 24 hr. Cells were washed and cultured in unsup- t
plemented SATO medium for an additional 24 hr prior to plating for P
neurite outgrowth assays as described. G
DRG neurons were isolated and dissociated from P5 rat pups as C
described above. The single-cell suspensions were then trans- c
fected with the wild-type p75, p75-FasTM, or p75-FasS receptor
H
chimeras via electroporation using the Amaxa Nucleofector Device
N
(Cologne, Germany). The neurons were then plated onto 100 g/ml
Hpoly-L-lysine in modified Sato media overnight at 37°C to allow for
texpression of the exogenous protein. Neurons were then removed
and plated onto monolayers of MAG-expressing or control CHO J
Kcells, and the neurite outgrowth assay was performed as indi-
cated above. Reagents
AG-Fc and MAG(1-3)-Fc chimeras were prepared in our lab as
reviously described (Tang et al., 1997). Unless otherwise stated,
ll reagents were purchased from Calbiochem, San Diego, CA.
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